Associate Professor Doan Ngo

NSW Health EMC Fellow

School of Biomedical Sciences and Pharmacy

Email:doan.ngo@newcastle.edu.au
Phone:(02) 40339386

Career Summary

Biography

Associate Professor Doan Ngo is an academic pharmacist and a successful basic and translational scientist with multiple important contributions in the cardiovascular and metabolic field. She is a co-director of Cardiometabolic, Vascular and Cardio-oncology Research Groups at the University of Newcastle and HMRI.

Career summary

Doan Ngo is an expert in cardiometabolic pathophysiology with focus on obesity, redox stress and vascular biology. She has made key contributions in the field of adipose tissue biology and angiogenesis and its effects on cardiovascular system.

Doan Ngo received her PhD in Medicine in December 2008. During her PhD, she developed an animal model of aortic stenosis and demonstrated that it can be prevented with ACE inhibitors. She has then demonstrated the effect of vitamin D deficiency on vascular function (Am J Med 2010; >100 citations).

During 2 years postdoctoral training in Boston and in the 3 years that followed, Doan Ngo rapidly gained significant expertise in obesity research and adipose tissue biology with over 10 top-tiered publications. She was one of the first to describe the role of the novel anti-angiogenic factor: VEGF-A165b in obesity and its complications. This work resulted in publications in most prestigious journals, including Circulation, Nature Medicine and Diabetes, and has been cited >200 times since 2014. She has also focussed on novel biomarker discovery and the mechanisms of their release and action in various cardiovascular disease states. This led to a lodgement of 2 patents with 1 more submitted as well as 2 publications and over 10 abstracts presented at major national and international meetings (CSANZ, ESC, AHA). Her research has been featured on the ABC, The Limbic and news.com.au.

She returned to Adelaide in June 2015 and started an independent research group. Within 9 months of return, working on a part-time (0.7 FTE) basis, she has lodged one patent, and 2 pending patent applications and had 3 senior author publications and grants in excess of $700,000. She was also honoured by being nominated as an outstanding cardiovascular research leader at the CSANZ 2015 meeting. As a testament to her abilities as an emerging leader in the cardiovascular field, she was appointed as Associate Professor, University of Newcastle in July 2017. Within 8 months, continuing to work at 0.7 FTE, the Cardiometabolic and Vascular research group, under her co-direction now consists of 1 postdoctoral fellow, 2 research assistants, 3 PhD students and 5 Honours students. In the short time with The University of Newcastle, Doan has been elected to the Faculty Board as a representative of the School of Biomedical Sciences and Pharmacy.

Together with A/Prof Aaron Sverdlov, Doan has established the first-in-Australia bench-to-bedside "Cancer and the Heart" program combining basic and clinical research into cancer therapy-related cardiotoxicity with Calvary Mater Newcastle Hospital-based clinical outpatient service. This program is a collaboration between Cancer Network, Cardiology, Oncology, Haematology and Radiation oncology departments and is supported by the grants from the Heart Foundation of Australia and NSW Ministry of Health.

Research Expertise

Doan Ngo's research encompasses a wide range of topics related to cardiovascular and metabolic health as well as a strong interest in cardiovascular complications of cancer therapies.

She has a basic and translational lab at the Hunter Medical Research Institute and a presence on the Callaghan Campus. Her clinical research, in partnership with A/Prof Sverdlov is at the John Hunter Hospital and Calvary Mater Newcastle.

Doan's specific research interests directions are:

Mechanisms underlying development of heart failure, especially heart failure due to obesity and diabetes
Role of angiogenesis, mitochondria and redox stress in cardiometabolic disorders with focus on obesity and diabetes
Mechanisms of development of cancer therapy-mediated cardiotoxicity
Role of novel biomarkers in early detection of various forms of heart disease
Basic and clinical factors reponsible for development and progression of aortic valve disease
Developing therapeutic options for cardio-protection in setting of cancer treatment
Development and evaluation of cardio-oncology clinical and translational program
Evaluation of new treatment options for patients with obesity, heart failure and chemotherapy-induced cardiotoxicity

Across these projects Doan has a number of local, national and international collaborators.

Track record, peer review and service to the field

Overall, Doan has >55 publications, of which >40 publications were published in the last 5 years, with over 50% of those as first, second, or senior author.

Doan Ngo is a current (2018-2021) NSW Ministry of Health EMC Fellow ($582,000). Her other key grants include: The Hospital Research Foundation Mid-Career Fellowship (2015-2018); Diabetes Australia Research Trust (2016-2018); Heart Foundation Vanguard Grant (2016-2018); Rebecca L Cooper Foundation Grant (2016-2017).

Doan Ngo is an Academic Editor for PLOS ONE and Heart, Lung and Circulation; Invited Editor for special focus issue in Mediators of Inflammation: "Interplay between Oxidative stress and Inflammation in Cardiometabolic Syndrome". She is a regular reviewer for NHMRC, ARC, and DART, European Society of Cardiology, American Heart Association, as well as 10 international biomedical journals. She is an invited member of NHMRC Cardiovascular GRP (2018 & 2019).

Supervision and mentoring

Since 2012, Doan Ngo has successfully supervised/co-supervised 4 PhD students to completion. She is a current mentor for a 2 postdoctoral fellows in cardiology. She is also a (co)-supervisor for 2 current PhD students. Additionally, Doan has a very successful track record mentoring medical students in research vacation projects: 3 of these medical students have won prizes at CSANZ 2016 & 2017, as well as multiple other awards including the Trevor Prescott Memorial Fellowship for overseas travel.

Collaborations

In addition to multiple collaborations within University of Newcastle, HMRI and Hunter New England Local Health District, Doan has active research collaborations with University of Adelaide, University of South Australia, University of Sydney, Boston University (USA) and University of East Anglia (UK).

Qualifications

Doctor of Philosophy, University of Adelaide
Bachelor of Pharmacy, University of South Australia
Bachelor of Health Science (Honours), University of Adelaide

Keywords

Angiogenesis
Biomarkers
Cardio-oncology
Cardiometabolic
Cardiovascular biology
Obesity and heart disease
Vascular biology

Languages

English (Fluent)
Vietnamese (Fluent)

Fields of Research

Code	Description	Percentage
110201	Cardiology (incl. Cardiovascular Diseases)	70
110107	Metabolic Medicine	20
111299	Oncology and Carcinogenesis not elsewhere classified	10

Professional Experience

UON Appointment

Title	Organisation / Department

Academic appointment

Dates	Title	Organisation / Department
1/1/2011 -	Fellow - European Society of Cardiology (FESC)	European Society of Cardiology France
1/1/2011 -	Fellow - Cardiac Society of Australia and New Zealand (FCSANZ)	Cardiac Society of Australia and NewZealand Australia

Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.

Book (1 outputs)

Year

Citation

Altmetrics

Link

2010

Chirkov YY, Sverdlov AL, Horowitz JD, Beneficial effects of perhexiline in cardiovascular disease states (2010)

© 2010 by Nova Science Publishers, Inc. All rights reserved. Perhexiline, 2-(2,2-dicyclohexylethyl)piperidine, was originally developed as a prophylactic anti-anginal drug in the late 1960s. It was initially a popular and effective treatment for angina, having the almost unique property compared to other agents available at that time, of not inducing reductions in blood pressure or heart rate. Despite the initial success, its use diminished markedly due to the occurrence during long-term therapy of poorly understood side effects (neurotoxicity and hepatotoxicity), which later were shown to be associated with high plasma concentrations of perhexiline, occurring in patients with relatively slow hepatic metabolism of the drug. However, therapeutic plasma monitoring and associated dose adjustments have led to perhexiline¿s reintroduction into clinical practice. This new book discusses the benefits of perhexiline in the treatment of cardiovascular disease.

Co-authors	Aaron Sverdlov

Journal article (72 outputs)

Year

Citation

Altmetrics

Link

2020

Diaz A, Sverdlov AL, Kelly B, Ngo DTM, Bates N, Garvey G, 'Nexus of cancer and cardiovascular disease for Australia's first peoples', Journal of Global Oncology, 2020 115-119 (2020) [C1]

DOI	10.1200/JGO.19.00088
Citations	Scopus - 1
Co-authors	Aaron Sverdlov, Brian Kelly

2019

Murtha L, Morten M, Schuliga M, Mabotuwana N, Hardy S, Waters D, et al., 'The Role of Pathological Aging in Cardiac and Pulmonary Fibrosis', Aging and Disease, 10 419-428 (2019) [C1]

DOI	10.14336/AD.2018.0601
Citations	Scopus - 9Web of Science - 11
Co-authors	Lucy Murtha, Michael Schuliga, Darryl Knight, Andrew Boyle, Aaron Sverdlov

2019

McGee M, Sugito S, Sverdlov AL, 'Cardiovascular Outcomes in Indigenous Australians: A National Gap', HEART LUNG AND CIRCULATION, 28 825-826 (2019)

DOI	10.1016/j.hlc.2019.04.001
Co-authors	Aaron Sverdlov

2019

Ezad S, Khan AA, Cheema H, Ashraf A, Ngo DTM, Sverdlov AL, Collins NJ, 'Ibrutinib-related atrial fibrillation: A single center Australian experience', Asia-Pacific Journal of Clinical Oncology, 15 e187-e190 (2019) [C1]

© 2019 John Wiley & Sons Australia, Ltd Background: Ibrutinib increases the risk of atrial fibrillation (AF) and is associated with bleeding tendencies. Reported rates of arrhythmia are variable in different studies. The aim of the current analysis was to evaluate the incidence of AF in a single-center cohort of patients. Methods: This analysis was conducted at Hunter New England Local Health District, Australia between April 1, 2015 and June 30, 2017. We included all consecutive patients commenced on ibrutinib for hematological malignancies. Patients with a history of paroxysmal AF were excluded. The primary end point was incidence of AF. Time to diagnosis and management were secondary outcomes of interest. Results: A total of 24 patients (age 73¿±¿9 years, males n¿=¿16 [67%]) were commenced on ibrutinib treatment during the study period with chronic lymphocytic leukemia (n¿=¿21, 88%) as the main indication. During a median follow-up of 12 months, four (17%) patients were diagnosed with AF with increasing age, duration of ibrutinib treatment as associations. The median time to AF diagnosis was 9 (interquartile range [IQR]: 7-18) months. All patients were managed with a rate control strategy with beta blockers as the preferred agents. Three (75%) patients were commenced on anticoagulation for stroke prevention. During a follow-up of 18 (IQR: 17-23) months following AF onset, one patient required hospitalization for AF. There were no bleeding complications reported. Conclusions: In conclusion, this series noted a higher incidence of AF than previously reported. Oncologists and cardiologists need to be aware of the increased risk of AF in patients receiving ibrutinib.

DOI	10.1111/ajco.13179
Citations	Web of Science - 1
Co-authors	Aaron Sverdlov

2019

Croft AJ, Ngo DTM, Sverdlov AL, 'Anthracycline-Induced Cardiotoxicity: Time to Focus on Cardioprotection Again', Heart Lung and Circulation, 28 1454-1456 (2019) [C1]

DOI	10.1016/j.hlc.2019.08.002
Co-authors	Aaron Sverdlov

2019

Ngo DTM, Sverdlov AL, Karki S, Macartney-Coxson D, Stubbs RS, Farb MG, et al., 'Oxidative modifications of mitochondrial complex ii are associated with insulin resistance of visceral fat in obesity', American Journal of Physiology - Endocrinology and Metabolism, 316 E168-E177 (2019) [C1]

© 2019 the American Physiological Society. Obesity, particularly visceral adiposity, has been linked to mitochondrial dysfunction and increased oxidative stress, which have been suggested as mechanisms of insulin resistance. The mechanism(s) behind this remains incompletely understood. In this study, we hypothesized that mitochondrial complex II dysfunction plays a role in impaired insulin sensitivity in visceral adipose tissue of subjects with obesity. We obtained subcutaneous and visceral adipose tissue biopsies from 43 subjects with obesity (body mass index = 30 kg/m 2 ) during planned bariatric surgery. Compared with subcutaneous adipose tissue, visceral adipose tissue exhibited decreased complex II activity, which was restored with the reducing agent dithiothreitol (5 mM) (P < 0.01). A biotin switch assay identified that cysteine oxidative posttranslational modifications (OPTM) in complex II subunit A (succinate dehydrogenase A) were increased in visceral vs. subcutaneous fat (P < 0.05). Insulin treatment (100 nM) stimulated complex II activity in subcutaneous fat (P < 0.05). In contrast, insulin treatment of visceral fat led to a decrease in complex II activity (P < 0.01), which was restored with addition of the mitochondria-specific oxidant scavenger mito-TEMPO (10 µ M). In a cohort of 10 subjects with severe obesity, surgical weight loss decreased OPTM and restored complex II activity, exclusively in the visceral depot. Mitochondrial complex II may be an unrecognized and novel mediator of insulin resistance associated with visceral adiposity. The activity of complex II is improved by weight loss, which may contribute to metabolic improvements associated with bariatric surgery.

DOI	10.1152/ajpendo.00227.2018
Citations	Scopus - 6Web of Science - 6
Co-authors	Aaron Sverdlov

2019

Figtree GA, Ngo DTM, Bubb KJ, 'Testosterone to estradiol ratio and plaque inflammation: Mechanistic insights and biomarker potential?', Cardiovascular Research, 115 255-257 (2019) [C1]

DOI	10.1093/cvr/cvy260

2018

Luptak I, Sverdlov AL, Panagia M, Qin F, Pimentel DR, Croteau D, et al., 'Decreased ATP production and myocardial contractile reserve in metabolic heart disease.', Journal of molecular and cellular cardiology, 116 106-114 (2018) [C1]

DOI	10.1016/j.yjmcc.2018.01.017
Citations	Scopus - 22Web of Science - 20
Co-authors	Aaron Sverdlov

2018

Efird JT, Jindal C, Kiser AC, Akhter SA, Crane PB, Kypson AP, et al., 'Increased risk of atrial fibrillation among patients undergoing coronary artery bypass graft surgery while receiving nitrates and antiplatelet agents', Journal of International Medical Research, 46 3183-3194 (2018) [C1]

© The Author(s) 2018. Background: Postoperative atrial fibrillation (POAF) is a frequent complication of coronary artery bypass graft (CABG) surgery. This arrhythmia occurs more frequently among patients who receive perioperative inotropic therapy (PINOT). Administration of nitrates with antiplatelet agents reduces the conversion rate of cyclic guanosine monophosphate to guanosine monophosphate. This process is associated with increased concentrations of free radicals, catecholamines, and blood plasma volume. We hypothesized that patients undergoing CABG surgery who receive PINOT may be more susceptible to POAF when nitrates are administered with antiplatelet agents. Methods: Clinical records were examined from a prospectively maintained cohort of 4,124 patients undergoing primary isolated CABG surgery to identify POAF-associated factors. Results: POAF risk was increased among patients receiving PINOT, and the greatest effect was observed when nitrates were administered with antiplatelet therapy. Adjustment for comorbidities did not substantively change the study results. Conclusions: Administration of nitrates with certain antiplatelet agents was associated with an increased POAF risk among patients undergoing CABG surgery. Additional studies are needed to determine whether preventive strategies such as administration of antioxidants will reduce this risk.

DOI	10.1177/0300060518773934
Co-authors	Aaron Sverdlov

2018

Surikow SY, Nguyen TH, Stafford I, Chapman M, Chacko S, Singh K, et al., 'Nitrosative Stress as a Modulator of Inflammatory Change in a Model of Takotsubo Syndrome.', JACC. Basic to translational science, 3 213-226 (2018)

DOI	10.1016/j.jacbts.2017.10.002

2017

Karki S, Ngo DTM, Farb MG, Park SY, Saggese SM, Hamburg NM, et al., 'WNT5A regulates adipose tissue angiogenesis via antiangiogenic VEGF-A(165)b in obese humans', AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 313 H200-H206 (2017)

DOI	10.1152/ajpheart.00776.2016
Citations	Scopus - 14Web of Science - 13

2017

Amarasekera AT, Assadi-Khansari B, Liu S, Black M, Dymmott G, Rogers NM, et al., 'Vitamin D supplementation lowers thrombospondin-1 levels and blood pressure in healthy adults', PLOS ONE, 12 (2017)

DOI	10.1371/journal.pone.0174435
Citations	Scopus - 4Web of Science - 3
Co-authors	Aaron Sverdlov

2017

Sverdlov AL, Ngo DTM, 'Response to the letter to editor: Galectin-3 and atrial fibrillation', INTERNATIONAL JOURNAL OF CARDIOLOGY, 229 2-2 (2017)

DOI	10.1016/j.ijcard.2016.12.006
Co-authors	Aaron Sverdlov

2017

Canavese M, Ngo DTM, Maddern GJ, Hardingham JE, Price TJ, Hauben E, 'Biology and therapeutic implications of VEGF-A splice isoforms and single-nucleotide polymorphisms in colorectal cancer', INTERNATIONAL JOURNAL OF CANCER, 140 2183-2191 (2017)

DOI	10.1002/ijc.30567
Citations	Scopus - 12Web of Science - 11

2016

Miller EJ, Calamaras T, Elezaby A, Sverdlov A, Qin F, Luptak I, et al., 'Partial Liver Kinase B1 (LKB1) Deficiency Promotes Diastolic Dysfunction, De Novo Systolic Dysfunction, Apoptosis, and Mitochondrial Dysfunction With Dietary Metabolic Challenge', JOURNAL OF THE AMERICAN HEART ASSOCIATION, 5 (2016)

DOI	10.1161/JAHA.115.002277
Citations	Scopus - 3Web of Science - 3
Co-authors	Aaron Sverdlov

2016

Sverdlov AL, Figtree GA, Horowitz JD, Ngo DTM, 'Interplay between Oxidative Stress and Inflammation in Cardiometabolic Syndrome', MEDIATORS OF INFLAMMATION, 2016 (2016)

DOI	10.1155/2016/8254590
Citations	Scopus - 4Web of Science - 6
Co-authors	Aaron Sverdlov

2016

Sverdlov AL, Elezaby A, Qin F, Behring JB, Luptak I, Calamaras TD, et al., 'Mitochondrial Reactive Oxygen Species Mediate Cardiac Structural, Functional, and Mitochondrial Consequences of Diet-Induced Metabolic Heart Disease', JOURNAL OF THE AMERICAN HEART ASSOCIATION, 5 (2016)

DOI	10.1161/JAHA.115.002555
Citations	Scopus - 49Web of Science - 41
Co-authors	Aaron Sverdlov

2016

Procter NEK, Ball J, Ngo DTM, Isenberg JS, Hylek EM, Chirkov YY, et al., 'Gender and tachycardia: independent modulation of platelet reactivity in patients with atrial fibrillation', JOURNAL OF GERIATRIC CARDIOLOGY, 13 202-208 (2016)

DOI	10.11909/j.issn.1671-5411.2016.03.005
Citations	Web of Science - 3

2016

Chen D, Procter N, Goh V, Liu S, Chua SJ, Assadi-Khansari B, et al., 'New onset atrial fibrillation is associated with elevated galectin-3 levels', International Journal of Cardiology, 223 48-49 (2016) [C1]

DOI	10.1016/j.ijcard.2016.08.172
Citations	Scopus - 12Web of Science - 10
Co-authors	Aaron Sverdlov

2016

Amarasekera AT, Sverdlov AL, Horowitz JD, Ngo DT, 'Elevated parathyroid hormone predicts high asymmetric dimethylarginine (ADMA) concentrations in obese diabetic patients', Diabetes and Metabolism, 42 378-381 (2016) [C1]

DOI	10.1016/j.diabet.2016.05.002
Citations	Scopus - 2Web of Science - 2
Co-authors	Aaron Sverdlov

2016

Procter NEK, Ball J, Ngo DTM, Chirkov YY, Isenberg JS, Hylek EM, et al., 'Platelet hyperaggregability in patients with atrial fibrillation Evidence of a background proinflammatory milieu', HERZ, 41 57-62 (2016)

DOI	10.1007/s00059-015-4335-y
Citations	Scopus - 7Web of Science - 8

2015

Sverdlov AL, Elezaby A, Behring JB, Bachschmid MM, Luptak I, Tu VH, et al., 'High fat, high sucrose diet causes cardiac mitochondrial dysfunction due in part to oxidative post-translational modification of mitochondrial complex II', JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 78 165-173 (2015) [C1]

DOI	10.1016/j.yjmcc.2014.07.018
Citations	Scopus - 46Web of Science - 45
Co-authors	Aaron Sverdlov

2015

Yao C, Behring JB, Shao D, Sverdlov AL, Whelan SA, Elezaby A, et al., 'Overexpression of Catalase Diminishes Oxidative Cysteine Modifications of Cardiac Proteins', PLOS ONE, 10 (2015) [C1]

DOI	10.1371/journal.pone.0144025
Citations	Scopus - 20Web of Science - 19
Co-authors	Aaron Sverdlov

2015

Taniguchi Y, Takahashi Y, Toba T, Yamada S, Yokoi K, Kobayashi S, et al., 'Poster Session 1: Sunday 3 May 2015, 08:30-18:00 * Room: Poster Area', European Heart Journal - Cardiovascular Imaging, 16 i11-i28 (2015)

DOI	10.1093/ehjci/jev051
Co-authors	Aaron Sverdlov

2015

Horowitz JD, Chong C-R, Ngo DT, Sverdlov AL, 'Effects of acute hyperglycaemia on cardiovascular homeostasis: does a spoonful of sugar make the flow-mediated dilatation go down?', JOURNAL OF THORACIC DISEASE, 7 E607-E611 (2015)

DOI	10.3978/j.issn.2072-1439.2015.12.40
Citations	Scopus - 3Web of Science - 3
Co-authors	Aaron Sverdlov

2015

Fuster JJ, Zuriaga MA, Doan T-MN, Farb MG, Aprahamian T, Yamaguchi TP, et al., 'Noncanonical Wnt Signaling Promotes Obesity-Induced Adipose Tissue Inflammation and Metabolic Dysfunction Independent of Adipose Tissue Expansion', DIABETES, 64 1235-1248 (2015)

DOI	10.2337/db14-1164
Citations	Scopus - 65Web of Science - 63

2015

Procter NEK, Ball J, Liu S, Hurst N, Nooney VB, Goh V, et al., 'Impaired platelet nitric oxide response in patients with new onset atrial fibrillation', INTERNATIONAL JOURNAL OF CARDIOLOGY, 179 160-165 (2015)

DOI	10.1016/j.ijcard.2014.10.137
Citations	Scopus - 15Web of Science - 17

2015

Karki S, Farb MG, Ngo DTM, Myers S, Puri V, Hamburg NM, et al., 'Forkhead Box O-1 Modulation Improves Endothelial Insulin Resistance in Human Obesity', ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 35 1498-1506 (2015)

DOI	10.1161/ATVBAHA.114.305139
Citations	Scopus - 23Web of Science - 22

2015

Liu S, Ngo DTM, Chong C-R, Amarasekera AT, Procter NEK, Licari G, et al., 'Suppression of neutrophil superoxide generation by BNP is attenuated in acute heart failure: a case for 'BNP resistance'', EUROPEAN JOURNAL OF HEART FAILURE, 17 475-483 (2015)

DOI	10.1002/ejhf.242
Citations	Scopus - 6Web of Science - 6

2015

Procter NEK, Ball J, Heresztyn T, Nooney VB, Liu S, Chong C-R, et al., 'Subtle renal dysfunction and bleeding risk in atrial fibrillation: symmetric dimethylarginine predicts HAS-BLED score', AMERICAN JOURNAL OF CARDIOVASCULAR DISEASE, 5 101-109 (2015)

2015

Chong C-R, Liu S, Licari G, Heresztyn T, Chirkov YY, Ngo DT, Horowitz JD, 'Reversal of hyperglycemia: effects on nitric oxide signaling.', Am J Med, 128 427-430 (2015)

DOI	10.1016/j.amjmed.2014.11.007

2015

Ngo DT, Gokce N, 'Epicardial adipose tissue: a benign consequence of obesity?', Circ Cardiovasc Imaging, 8 (2015)

DOI	10.1161/CIRCIMAGING.115.003156

2015

Elezaby A, Sverdlov AL, Tu VH, Soni K, Luptak I, Qin F, et al., 'Mitochondrial remodeling in mice with cardiomyocyte-specific lipid overload', JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 79 275-283 (2015) [C1]

DOI	10.1016/j.yjmcc.2014.12.001
Citations	Scopus - 33Web of Science - 33
Co-authors	Aaron Sverdlov

2014

Procter NEK, Chong C-R, Sverdlov AL, Chan WPA, Chirkov YY, Horowitz JD, 'Aging of Platelet Nitric Oxide Signaling: Pathogenesis, Clinical Implications, and Therapeutics', SEMINARS IN THROMBOSIS AND HEMOSTASIS, 40 660-668 (2014)

DOI	10.1055/s-0034-1389082
Citations	Scopus - 8Web of Science - 6
Co-authors	Aaron Sverdlov

2014

Chong C-R, Chan WPA, Nguyen TH, Liu S, Procter NEK, Ngo DT, et al., 'Thioredoxin-Interacting Protein: Pathophysiology and Emerging Pharmacotherapeutics in Cardiovascular Disease and Diabetes', CARDIOVASCULAR DRUGS AND THERAPY, 28 347-360 (2014)

DOI	10.1007/s10557-014-6538-5
Citations	Scopus - 48Web of Science - 46
Co-authors	Aaron Sverdlov

2014

Ahmadian A, Brogan A, Berman J, Sverdlov AL, Mercier G, Mazzini M, et al., 'Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis', JOURNAL OF NUCLEAR CARDIOLOGY, 21 925-939 (2014)

DOI	10.1007/s12350-014-9901-9
Citations	Scopus - 73Web of Science - 68
Co-authors	Aaron Sverdlov

2014

Sverdlov AL, Ngo DTM, Chan WPA, Chirkov YY, Horowitz JD, 'Aging of the Nitric Oxide System: Are We as Old as Our NO?', JOURNAL OF THE AMERICAN HEART ASSOCIATION, 3 (2014)

DOI	10.1161/JAHA.114.000973
Citations	Scopus - 31Web of Science - 27
Co-authors	Aaron Sverdlov

2014

Karki S, Ngo DTM, Bigornia SJ, Farb MG, Gokce N, 'Insulin resistance: a key therapeutic target for cardiovascular risk reduction in obese patients?', EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 9 93-95 (2014)

DOI	10.1586/17446651.2014.878646
Citations	Web of Science - 1

2014

Ngo DTM, Farb MG, Kikuchi R, Karki S, Tiwari S, Bigornia SJ, et al., 'Antiangiogenic Actions of Vascular Endothelial Growth Factor-A(165)b, an Inhibitory Isoform of Vascular Endothelial Growth Factor-A, in Human Obesity', CIRCULATION, 130 1072-1080 (2014)

DOI	10.1161/CIRCULATIONAHA.113.008171
Citations	Scopus - 46Web of Science - 45

2014

Kikuchi R, Nakamura K, MacLauchlan S, Doan T-MN, Shimizu I, Fuster JJ, et al., 'An antiangiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery disease', NATURE MEDICINE, 20 1464-1471 (2014)

DOI	10.1038/nm.3703
Citations	Scopus - 101Web of Science - 100

2014

Liu S, Ngo DTM, Stewart S, Horowitz JD, Chirkov YY, 'B-Type natriuretic peptide suppression of neutrophil superoxide generation: mechanistic studies in normal subjects', CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 41 739-743 (2014)

DOI	10.1111/1440-1681.12291
Citations	Web of Science - 7

2014

Farb MG, Tiwari S, Karki S, Ngo DTM, Carmine B, Hess DT, et al., 'Cyclooxygenase Inhibition Improves Endothelial Vasomotor Dysfunction of Visceral Adipose Arterioles in Human Obesity', OBESITY, 22 349-355 (2014)

DOI	10.1002/oby.20505
Citations	Scopus - 21Web of Science - 20

2013

Chan WPA, Ngo DT, Sverdlov AL, Rajendran S, Stafford I, Heresztyn T, et al., 'Premature Aging of Cardiovascular/Platelet Function in Polycystic Ovarian Syndrome', AMERICAN JOURNAL OF MEDICINE, 126 (2013) [C1]

DOI	10.1016/j.amjmed.2012.12.015
Citations	Scopus - 8Web of Science - 4
Co-authors	Aaron Sverdlov

2013

Maher AR, Arif S, Madhani M, Abozguia K, Ahmed I, Fernandez BO, et al., 'Impact of chronic congestive heart failure on pharmacokinetics and vasomotor effects of infused nitrite', BRITISH JOURNAL OF PHARMACOLOGY, 169 659-670 (2013) [C1]

DOI	10.1111/bph.12152
Citations	Scopus - 19Web of Science - 18
Co-authors	Aaron Sverdlov

2013

Sverdlov AL, Chan WPA, Procter NEK, Chirkov YY, Ngo DTM, Horowitz JD, 'Reciprocal regulation of NO signaling and TXNIP expression in humans: Impact of aging and ramipril therapy', INTERNATIONAL JOURNAL OF CARDIOLOGY, 168 4624-4630 (2013)

DOI	10.1016/j.ijcard.2013.07.159
Citations	Scopus - 22Web of Science - 25
Co-authors	Aaron Sverdlov

2013

Ngo DTM, Horowitz JD, Sverdlov AL, 'Heart Failure A Corin-Deficient State?', HYPERTENSION, 61 284-285 (2013)

DOI	10.1161/HYPERTENSIONAHA.112.196253
Citations	Scopus - 7Web of Science - 7
Co-authors	Aaron Sverdlov

2013

Nguyen TH, Neil CJ, Sverdlov AL, Ngo DT, Chan WP, Heresztyn T, et al., 'Enhanced NO Signaling in Patients with Takotsubo Cardiomyopathy: Short-Term Pain, Long-Term Gain?', CARDIOVASCULAR DRUGS AND THERAPY, 27 541-547 (2013)

DOI	10.1007/s10557-013-6481-x
Citations	Scopus - 15Web of Science - 8
Co-authors	Aaron Sverdlov

2013

Dautov RF, Ngo DTM, Licari G, Liu S, Sverdlov AL, Ritchie RH, et al., 'The nitric oxide redox sibling nitroxyl partially circumvents impairment of platelet nitric oxide responsiveness', NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 35 72-78 (2013)

DOI	10.1016/j.niox.2013.08.006
Citations	Scopus - 17Web of Science - 17
Co-authors	Aaron Sverdlov

2012

Neil C, Thanh HN, Kucia A, Crouch B, Sverdlov A, Chirkov Y, et al., 'Slowly resolving global myocardial inflammation/oedema in Tako-Tsubo cardiomyopathy: evidence from T2-weighted cardiac MRI', HEART, 98 1278-1284 (2012)

DOI	10.1136/heartjnl-2011-301481
Citations	Scopus - 53Web of Science - 50
Co-authors	Aaron Sverdlov

2012

Ngo DT, Sverdlov AL, Horowitz JD, 'Prevention of aortic valve stenosis: A realistic therapeutic target?', PHARMACOLOGY & THERAPEUTICS, 135 78-93 (2012)

DOI	10.1016/j.pharmthera.2012.04.001
Citations	Scopus - 17Web of Science - 15
Co-authors	Aaron Sverdlov

2012

Sverdlov AL, Ngo DT, Horowitz JD, 'Redefining the natural history of calcific aortic stenosis: lessons from Laennec', JOURNAL OF INTERNAL MEDICINE, 271 569-572 (2012)

DOI	10.1111/j.1365-2796.2012.02520.x
Citations	Scopus - 1Web of Science - 1
Co-authors	Aaron Sverdlov

2012

Sverdlov AL, Ngo DTM, Chan WPA, Chirkov YY, Gersh BJ, McNeil JJ, Horowitz JD, 'Determinants of aortic sclerosis progression: Implications regarding impairment of nitric oxide signalling and potential therapeutics', European Heart Journal, 33 2419-2425 (2012) [C1]

DOI	10.1093/eurheartj/ehs171
Citations	Scopus - 20Web of Science - 18
Co-authors	Aaron Sverdlov

2012

Neil CJ, Nguyen TH, Sverdlov AL, Chirkov YY, Chong C-R, Stansborough J, et al., 'Can we make sense of takotsubo cardiomyopathy? An update on pathogenesis, diagnosis and natural history', EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 10 215-221 (2012)

Citations	Scopus - 19Web of Science - 10
Co-authors	Aaron Sverdlov

2012

Sverdlov AL, Ngo DTM, Horowitz JD, 'Pathogenesis of aortic sclerosis: association with low BMI, tissue nitric oxide resistance, but not systemic inflammatory activation', AMERICAN JOURNAL OF CARDIOVASCULAR DISEASE, 2 43-49 (2012)

Citations	Web of Science - 3
Co-authors	Aaron Sverdlov

2011

Ngo DTM, Stafford I, Sverdlov AL, Qi W, Wuttke RD, Zhang Y, et al., 'Ramipril retards development of aortic valve stenosis in a rabbit model: Mechanistic considerations', British Journal of Pharmacology, 162 722-732 (2011) [C1]

DOI	10.1111/j.1476-5381.2010.01084.x
Citations	Scopus - 26Web of Science - 25
Co-authors	Aaron Sverdlov

2011

Sverdlov AL, Ngo DT, Chapman MJ, Ali OA, Chirkov YY, Horowitz JD, 'Pathogenesis of aortic stenosis: not just a matter of wear and tear.', Am J Cardiovasc Dis, 1 185-199 (2011)

Citations	Web of Science - 11
Co-authors	Aaron Sverdlov

2011

Nguyen TH, Neil CJ, Sverdlov AL, Mahadavan G, Chirkov YY, Kucia AM, et al., 'N-Terminal Pro-Brain Natriuretic Protein Levels in Takotsubo Cardiomyopathy', AMERICAN JOURNAL OF CARDIOLOGY, 108 1316-1321 (2011)

DOI	10.1016/j.amjcard.2011.06.047
Citations	Scopus - 74Web of Science - 66
Co-authors	Aaron Sverdlov

2011

Ling L-H, Chik W, Averbuj P, Pati PK, Sverdlov AL, Ngo DTM, et al., 'Effects of Aging, Renal Dysfunction, Left Ventricular Systolic Impairment, and Weight on Steady State Pharmacokinetics of Perhexiline', THERAPEUTIC DRUG MONITORING, 33 251-256 (2011)

DOI	10.1097/FTD.0b013e31820dd8e9
Citations	Scopus - 4Web of Science - 4
Co-authors	Aaron Sverdlov

2011

Nightingale AK, Sverdlov AL, Rajendran S, Mishra K, Heresztyn T, Ngo DTM, Horowitz JD, 'Lack of association between aortic sclerosis and left ventricular hypertrophy in elderly subjects', INTERNATIONAL JOURNAL OF CARDIOLOGY, 150 33-38 (2011)

DOI	10.1016/j.ijcard.2010.02.024
Citations	Scopus - 9Web of Science - 7
Co-authors	Aaron Sverdlov

2011

Sverdlov AL, Ngo DTM, Nightingale AK, Rajendran S, Mishra K, Heresztyn T, et al., 'The endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) predicts LV mass independent of afterload', NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 25 41-46 (2011)

DOI	10.1016/j.niox.2011.04.009
Citations	Scopus - 9Web of Science - 10
Co-authors	Aaron Sverdlov

2011

Ngo DTM, Chan WP, Rajendran S, Heresztyn T, Amarasekera A, Sverdlov AL, et al., 'Determinants of insulin responsiveness in young women: Impact of polycystic ovarian syndrome, nitric oxide, and vitamin D', NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 25 326-330 (2011)

DOI	10.1016/j.niox.2011.06.005
Citations	Scopus - 44Web of Science - 35
Co-authors	Aaron Sverdlov

2010

Horowitz JD, Chirkov YY, Kennedy JA, Sverdlov AL, 'Modulation of myocardial metabolism: An emerging therapeutic principle', Current Opinion in Cardiology, 25 329-334 (2010)

DOI	10.1097/HCO.0b013e328339f191
Citations	Scopus - 39Web of Science - 37
Co-authors	Aaron Sverdlov

2010

Ngo DT, Sverdlov AL, McNeil JJ, Horowitz JD, 'Does Vitamin D Modulate Asymmetric Dimethylarginine and C-Reactive Protein Concentrations?', AMERICAN JOURNAL OF MEDICINE, 123 335-341 (2010)

DOI	10.1016/j.amjmed.2009.09.024
Citations	Scopus - 91Web of Science - 80
Co-authors	Aaron Sverdlov

2010

Chirkov YY, De Sciscio M, Sverdlov AL, Leslie S, Sage PR, Horowitz JD, 'Hydralazine does not Ameliorate Nitric Oxide Resistance in Chronic Heart Failure', CARDIOVASCULAR DRUGS AND THERAPY, 24 131-137 (2010)

DOI	10.1007/s10557-010-6233-0
Citations	Scopus - 8Web of Science - 6
Co-authors	Aaron Sverdlov

2009

Ngo DTM, Sverdlov AL, McNeil JJ, Horowitz JD, 'Correlates of arterial stiffness in an ageing population: Role of asymmetric dimethylarginine', PHARMACOLOGICAL RESEARCH, 60 503-507 (2009)

DOI	10.1016/j.phrs.2009.06.006
Citations	Scopus - 14Web of Science - 11
Co-authors	Aaron Sverdlov

2009

Ngo DTM, Sverdlov AL, Willoughby SR, Nightingale AK, Chirkov YY, McNeil JJ, Horowitz JD, 'Determinants of Occurrence of Aortic Sclerosis in an Aging Population', JACC-CARDIOVASCULAR IMAGING, 2 919-927 (2009)

DOI	10.1016/j.jcmg.2009.03.016
Citations	Scopus - 37Web of Science - 37
Co-authors	Aaron Sverdlov

2008

Sverdlov AL, Taylor K, Elkington AG, Zeitz CJ, Beltrame JF, 'Cardiac magnetic resonance imaging identifies the elusive perivalvular abscess', CIRCULATION, 118 E1-E3 (2008)

DOI	10.1161/CIRCULATIONAHA.107.727339
Citations	Scopus - 2Web of Science - 2
Co-authors	Aaron Sverdlov

2008

Ngo DTM, Stafford I, Kelly DJ, Sverdlov AL, Wuttke RD, Weedon H, et al., 'Vitamin D(2) supplementation induces the development of aortic stenosis in rabbits: Interactions with endothelial function and thioredoxin-interacting protein', EUROPEAN JOURNAL OF PHARMACOLOGY, 590 290-296 (2008)

DOI	10.1016/j.ejphar.2008.05.051
Citations	Scopus - 28Web of Science - 32
Co-authors	Aaron Sverdlov

2008

Chan WPA, Sverdlov AL, Horowitz JD, 'Management of the metabolic syndrome in cardiovascular disease', Current Treatment Options in Cardiovascular Medicine, 10 27-38 (2008)

The main components of the metabolic syndrome (MS) are abdominal obesity, atherogenic dyslipidemia, raised blood pressure, insulin resistance with or without glucose intolerance, ... [more]

The main components of the metabolic syndrome (MS) are abdominal obesity, atherogenic dyslipidemia, raised blood pressure, insulin resistance with or without glucose intolerance, and proinflammatory and prothrombotic states. The clustering of these metabolic risk factors significantly increases the risk of type 2 diabetes and promotes vascular endothelial dysfunction, inflammation, and increased oxidative stress. The net result is an increase in the risk of atherosclerotic cardiovascular disease. Therefore, management of MS is of utmost importance, especially considering its rapidly increasing prevalence in a population with rising obesity rates and its significant cardiovascular implications. The primary management of this syndrome involves the correction of the underlying risk factors - obesity, physical inactivity, and an atherogenic diet - with lifestyle modifications including increased physical activity and dietary modification. Smoking cessation also should be encouraged. However, pharmacologic therapies are often required to address cardiovascular risk factors. These agents can be categorized broadly into 1) anorectic agents, 2) insulin-sensitizing agents, 3) statins, and 4) renin-angiotensin system antagonists. Emerging therapies include adipokines, endocannabinoid inhibitors, and metabolic modulators, such as perhexiline and trimetazidine. To date, these therapies have not been shown to normalize the metabolic and cardiovascular burden of MS, and there still is no single therapeutic agent for its management. Copyright © 2008 by Current Medicine Group LLC.

DOI	10.1007/s11936-008-0004-2
Citations	Scopus - 1
Co-authors	Aaron Sverdlov

2007

Ngo DTM, Heresztyn T, Mishra K, Marwick TH, Horowitz JD, 'Aortic stenosis is associated with elevated plasma levels of asymmetric dimethylarginine (ADMA)', NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 16 197-201 (2007)

DOI	10.1016/j.niox.2006.10.003
Citations	Scopus - 33Web of Science - 33

2004

Ngo DTM, Wuttke RD, Turner S, Marwick TH, Horowitz JD, 'Quantitative assessment of aortic sclerosis using ultrasonic backscatter', JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY, 17 1123-1130 (2004)

DOI	10.1016/j.echo.2004.06.012
Citations	Scopus - 22Web of Science - 24

1973

McLaren J, Ngo DT, Olivera BM, 'Pyridine nucleotide metabolism in Escherichia coli. 3. Biosynthesis from alternative precursors in vivo.', The Journal of biological chemistry, 248 5144-5149 (1973)

Show 69 more journal articles

Conference (15 outputs)

Year

Citation

Altmetrics

Link

2016

Chua SJ, Ajaero C, Assadi-Khansari B, McGavigan A, Horowitz JD, Sverdlov AL, Ngo DTM, 'Galectin 3 is markedly elevated in severe heart failure and predicts improvement in LV volumes post cardiac resynchronisation therapy', EUROPEAN HEART JOURNAL, Rome, ITALY (2016)

Co-authors	Aaron Sverdlov

2016

Assadi-Khansari B, Chua SJ, Chapman M, Ali O, Nguyen H, Horowitz JD, et al., 'Follistatin-like 3 predicts aortic root enlargement in patients with bicuspid aortic valve', EUROPEAN HEART JOURNAL, Rome, ITALY (2016)

Co-authors	Aaron Sverdlov

2016

Chua SJ, Ajaero C, Assadi-Khansari B, Mcgavigan A, Horowitz JD, Ngo DT, Sverdlov AL, 'Galectin 3 predicts improvement in LV volumes after Cardiac Resynchronisation Therapy', EUROPEAN JOURNAL OF HEART FAILURE (2016)

Co-authors	Aaron Sverdlov

2016

Procter NEK, Ball J, Ngo DTM, Chirkov YY, Stewart S, Horowitz JD, 'Platelet hypo-responsiveness to nitric oxide in new onset atrial fibrillation has a physiological, as opposed to pharmacological, basis', EUROPEAN HEART JOURNAL, Rome, ITALY (2016)

2016

Liu S, Assadi-Khansari B, Ajaero C, Chua SJ, Horowitz JD, Ngo DT, Sverdlov AL, 'Follistatin-Like 3 is Elevated In Acute Heart Failure Patients', CIRCULATION, Pentagon City, VA (2016)

Co-authors	Aaron Sverdlov

2016

Karki S, Ngo DTM, Farb MG, Carmine B, Hess DT, Gokce N, 'Wnt5a in Adipose Tissue Regulates Angiogenesis via Activation of Antiangiogenic Isoform VEGFA(165)b in Obese Subjects', DIABETES, New Orleans, LA (2016)

2014

Procter NEK, Ball J, Ngo DTM, Chirkov YY, Isenberg JS, Hylek EM, et al., 'Gender/tachycardia interactions in atrial fibrillation: impact upon platelet aggregation and nitric oxide signalling', EUROPEAN HEART JOURNAL, Barcelona, SPAIN (2014)

2013

Amarasekera AT, Sverdlov AL, Roberts MS, Horowitz JD, Ngo DT, 'Elevated parathyroid hormone predicts high asymmetric dimethylarginine (ADMA) concentrations; independent of vitamin D status', EUROPEAN HEART JOURNAL, Amsterdam, NETHERLANDS (2013)

Citations	Web of Science - 1
Co-authors	Aaron Sverdlov

2011

Ngo DTM, Chan WPA, Sverdlov AL, Horowitz JD, 'Determinants and cardiovascular correlates of vitamin D deficiency in australian women', EUROPEAN HEART JOURNAL (2011)

Co-authors	Aaron Sverdlov

2011

Sverdlov AL, Ngo DTM, Chirkov YY, Horowitz JD, 'Insights into the initiation of aortic stenosis: roles of ACE-inhibitors and vitamin D', EUROPEAN HEART JOURNAL (2011)

Co-authors	Aaron Sverdlov

2011

Ngo DTM, Chan WPA, Sverdlov AL, Horowitz JD, 'Determinants and cardiovascular correlates of vitamin D deficiency in australian women', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)

Co-authors	Aaron Sverdlov

2011

Sverdlov AL, Ngo DTM, Chirkov YY, Horowitz JD, 'Insights into the initiation of aortic stenosis: roles of ACE-inhibitors and vitamin D', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)

Co-authors	Aaron Sverdlov

2009

Ngo DTM, Sverdlov AL, Mcneil JJ, Horowitz JD, 'Low 25-hydroxyvitamin D levels are associated with elevated plasma ADMA and C-reactive protein concentrations: nexus with cardiovascular disease', EUROPEAN HEART JOURNAL (2009)

Co-authors	Aaron Sverdlov

2007

Ngo DTM, Sverdlov AL, Willoughby SR, Nightingale AK, Chirkov YY, Mcneil JJ, Horowitz JD, 'Aortic valve sclerosis is associated with impaired platelet responsiveness to nitric oxide', EUROPEAN HEART JOURNAL (2007)

Co-authors	Aaron Sverdlov

2007

Ngo DTM, Stafford I, Wuttke RD, Weedon H, Smith MD, Sverdlov AL, et al., 'Ramipril retards progression of aortic valve stenosis: association with preservation of nitric oxide effects', EUROPEAN HEART JOURNAL (2007)

Co-authors	Aaron Sverdlov

Show 12 more conferences

Edit

Grants and Funding

Summary

Number of grants	13
Total funding	$1,926,840

Click on a grant title below to expand the full details for that specific grant.

20202 grants / $793,786

Can we treat cancer without breaking the heart? From cardiotoxicity to cardioprotection – reversing the impact of cancer therapies on cardiovascular health for cancer patients. $736,786

Funding body: NSW Ministry of Health

Funding body	NSW Ministry of Health
Project Team	Associate Professor Aaron Sverdlov, Doctor Anthony Proietto, Conjoint Professor Tom Walley, Professor John Attia, Professor John Wiggers, Associate Professor Doan Ngo, Laureate Professor Rodney Scott, Gemma Figtree, Paul Burridge, Alex Lyon, Wilson Colucci, Daniel Lenihan
Scheme	Early-Mid Career Researcher Grant
Role	Investigator
Funding Start	2020
Funding Finish	2022
GNo	G1901542
Type Of Funding	C2220 - Aust StateTerritoryLocal - Other
Category	2220
UON	Y

Better understanding of real-life incidence and treatment of iron deficiency and its impact on outcomes in heart failure patients in regional and rural Australia$57,000

Funding body: Hunter Medical Research Institute

Funding body	Hunter Medical Research Institute
Project Team	Associate Professor Aaron Sverdlov, Associate Professor Doan Ngo
Scheme	Research Grant
Role	Investigator
Funding Start	2020
Funding Finish	2022
GNo	G2000567
Type Of Funding	C3120 - Aust Philanthropy
Category	3120
UON	Y

20194 grants / $189,292

To further develop and test a new paradigm for the management of changing Heart Failure$99,166

Funding body: Biotronik Australia Pty Ltd

Funding body	Biotronik Australia Pty Ltd
Project Team	Associate Professor Aaron Sverdlov, Professor Andrew Boyle, Associate Professor Doan Ngo
Scheme	Entrepreneurs' Programme: Innovation Connections
Role	Investigator
Funding Start	2019
Funding Finish	2019
GNo	G1901143
Type Of Funding	C3111 - Aust For profit
Category	3111
UON	Y

Better understanding of mechanisms underlying heart failure due to obesity$50,000

Funding body: Royal Australasian College of Physicians

Funding body	Royal Australasian College of Physicians
Project Team	Associate Professor Aaron Sverdlov, Associate Professor Doan Ngo
Scheme	Foundation for High Blood Pressure Research Establishment Fellowship
Role	Investigator
Funding Start	2019
Funding Finish	2019
GNo	G1801367
Type Of Funding	C3112 - Aust Not for profit
Category	3112
UON	Y

Novel discovery of Sirtuin-3 isoforms in human cardiomyocytes$20,063

Funding body: John Hunter Hospital Charitable Trust

Funding body	John Hunter Hospital Charitable Trust
Project Team	Associate Professor Aaron Sverdlov, Ms Amanda Croft, Associate Professor Doan Ngo
Scheme	Research Grant
Role	Investigator
Funding Start	2019
Funding Finish	2019
GNo	G1900118
Type Of Funding	C2220 - Aust StateTerritoryLocal - Other
Category	2220
UON	Y

Profiling of circulation microRNAs in patients with non ST-segment elevation (NSTEMI) myocardial infarction.$20,063

Funding body: John Hunter Hospital Charitable Trust

Funding body	John Hunter Hospital Charitable Trust
Project Team	Associate Professor Doan Ngo, Conjoint Associate Professor James Leitch, Ms Alex Nesbitt
Scheme	Research Grant
Role	Lead
Funding Start	2019
Funding Finish	2019
GNo	G1900129
Type Of Funding	C2220 - Aust StateTerritoryLocal - Other
Category	2220
UON	Y

20184 grants / $743,762

Implementation of strategies for early detection and prevention of chemotherapy-induced cardiotoxicity in cancer patients: a multidisciplinary approach$582,391

Funding body: NSW Ministry of Health

Funding body	NSW Ministry of Health
Project Team	Associate Professor Doan Ngo
Scheme	Early-Mid Career Fellowships
Role	Lead
Funding Start	2018
Funding Finish	2020
GNo	G1701368
Type Of Funding	C2220 - Aust StateTerritoryLocal - Other
Category	2220
UON	Y

To develop and test a new paradigm for management of changing Heart Failure disease treatment$99,371

Funding body: Biotronik Australia Pty Ltd

Funding body	Biotronik Australia Pty Ltd
Project Team	Associate Professor Aaron Sverdlov, Associate Professor Doan Ngo, Professor Andrew Boyle
Scheme	Entrepreneurs' Programme: Innovation Connections
Role	Investigator
Funding Start	2018
Funding Finish	2018
GNo	G1801209
Type Of Funding	C3111 - Aust For profit
Category	3111
UON	Y

Identification of novel biomarkers to predict early onset chemotherapy-induced cardiovascular toxicities$37,000

Funding body: Hunter Medical Research Institute

Funding body	Hunter Medical Research Institute
Project Team	Associate Professor Doan Ngo, Associate Professor Aaron Sverdlov, Dr Anoop Enjeti, Prof Philip Rowlings, Associate Professor Anthony Proietto
Scheme	Project Grant
Role	Lead
Funding Start	2018
Funding Finish	2018
GNo	G1801448
Type Of Funding	C3120 - Aust Philanthropy
Category	3120
UON	Y

Determining the mechanisms of myocardial infarction induced cardiac fibrosis: what role does fibulin-3 play?$25,000

Funding body: Hunter Medical Research Institute

Funding body	Hunter Medical Research Institute
Project Team	Doctor Lucy Murtha, Professor Andrew Boyle, Associate Professor Doan Ngo, Associate Professor Aaron Sverdlov
Scheme	Project Grant
Role	Investigator
Funding Start	2018
Funding Finish	2018
GNo	G1801370
Type Of Funding	C3120 - Aust Philanthropy
Category	3120
UON	Y

20172 grants / $175,000

Cardiometabolic research program$100,000

Funding body: Hunter New England Local Health District

Funding body	Hunter New England Local Health District
Project Team	Associate Professor Aaron Sverdlov, Associate Professor Doan Ngo
Scheme	Project Grant
Role	Investigator
Funding Start	2017
Funding Finish	2017
GNo	G1701207
Type Of Funding	C3112 - Aust Not for profit
Category	3112
UON	Y

Beetroot supplementation and exercise tolerance: another way to boost physical activity to combat obesity?$75,000

Funding body: National Heart Foundation of Australia

Funding body	National Heart Foundation of Australia
Project Team	Associate Professor Aaron Sverdlov, Associate Professor Doan Ngo, Professor John Horowitz, AM
Scheme	Vanguard Grant
Role	Investigator
Funding Start	2017
Funding Finish	2017
GNo	G1701324
Type Of Funding	Aust Competitive - Non Commonwealth
Category	1NS
UON	Y

20161 grants / $25,000

Metabolic heart disease: markers and mechanisms$25,000

Funding body: Rebecca L Cooper Medical Research Foundation Ltd

Funding body	Rebecca L Cooper Medical Research Foundation Ltd
Project Team	Associate Professor Aaron Sverdlov, Associate Professor Doan Ngo
Scheme	Research Grant
Role	Investigator
Funding Start	2016
Funding Finish	2017
GNo	G1701494
Type Of Funding	C3112 - Aust Not for profit
Category	3112
UON	Y

Edit

Research Supervision

Number of supervisions

Completed5

Current6

Current Supervision

Commenced	Level of Study	Research Title	Program	Supervisor Type
2020	PhD	The Origin of Extracellular Matrix Protein 1 (ECM) Production in Cardiac Ageing and Myocardial Infarction	PhD (Medicine), Faculty of Health and Medicine, The University of Newcastle	Co-Supervisor
2020	PhD	Can Improving Redox State in Obesity Protect the Heart from Failure and the Gut from Cancer?	PhD (Medicine), Faculty of Health and Medicine, The University of Newcastle	Co-Supervisor
2020	PhD	Improving Cardiovascular Outcomes for Cancer Patients and Survivors: Focus on Novel Biomarkers for Risk Stratification	PhD (Medical Biochemistry), Faculty of Health and Medicine, The University of Newcastle	Principal Supervisor
2019	PhD	Pathophysiology of Obesity-Induced Cardiometabolic Dysfunction: The Link With Colorectal Cancer	PhD (Pharmacy), Faculty of Health and Medicine, The University of Newcastle	Principal Supervisor
2019	PhD	Improving Outcomes following Hospitalisation for Heart Failure in Regional and Remote NSW-the BEEM-HF Study	PhD (Medicine), Faculty of Health and Medicine, The University of Newcastle	Co-Supervisor
2018	PhD	Early Detection of Cardiotoxicity from Chemotherapy	PhD (Pharmacy), Faculty of Health and Medicine, The University of Newcastle	Principal Supervisor

Past Supervision

Year	Level of Study	Research Title	Program	Supervisor Type
2017	Honours	Role of follistatin-like 3 in chemotherapy-induced cardiotoxicity	Medical Science, The University of Adelaide	Co-Supervisor
2015	PhD	Variability of Nitric Oxide signalling in atrial fibrillation: Potential modulation	Medical Science, The University of Adelaide	Co-Supervisor
2015	PhD	Impaired tissue responsiveness to Brain Natriuretic Peptide in Heart Failure: Biochemical bases	Medical Science, University of Adelaide	Co-Supervisor
2014	PhD	Effects of nitrite and nitroxyl on human vascular and platelet function	Medical Science, The University of Adelaide	Co-Supervisor
2014	PhD	Does vitamin D deficiency contribute to endothelial dysfunction	Pharmacy, The University of South Australia	Co-Supervisor

Edit

News

Hearty success in NSW Medical Research Cardiovascular grants

May 7, 2020

Heart disease kills one person every 12 minutes in Australia, and is still the leading cause of death globally. Despite enormous improvements in health outcomes over the years, heart disease is still one of the biggest health burdens on our economy.

Funding success to aid early interventions for cancer and stroke

July 16, 2018

Two exceptional Early to Mid-Career Researchers have secured more than $1.16 million to explore early intervention methods for two significant health challenges